Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2009 by Universitair Ziekenhuis Brussel.
Recruitment status was:  Recruiting
Merck Serono International SA
Information provided by:
Universitair Ziekenhuis Brussel Identifier:
First received: August 6, 2009
Last updated: January 7, 2010
Last verified: August 2009

August 6, 2009
January 7, 2010
September 2005
January 2008   (Final data collection date for primary outcome measure)
pregnancy occurrence, pregnancy loss [ Time Frame: 14 days after OPU ]
Same as current
Complete list of historical versions of study NCT00954811 on Archive Site
hormone levels, OHSS, endometrium [ Time Frame: 14 days after oocyte pick up ]
Same as current
Not Provided
Not Provided
Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)
A Phase IV Study on the Effect of Luteal Supplementation With Rec-LH on the Pregnancy Rate After Ovulation Triggering With GnRH-agonist Instead of HCG in IVF Protocol;Proof of Concept
Our aim is to access whether we can achieve equivalent pregnancy rates by the addition of six doses of luteal support with recLH after agonist triggering for IVF cycles in the absence of OHSS.
Whether pregnancy outcome after GnRH-agonist triggering could be improved by adding luteal recLH support plus progesterone, compared to that observed after ovulation triggering with HCG in GnRH antagonist stimulated cycles.
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
  • Pregnancy
  • Pregnancy Loss
  • Drug: 300IU rec-LH
    luteal alternate doses
  • Drug: progesterone 600mg
    luteal support
  • Active Comparator: HCG for ovulation triggering and luteal progesterone
    conventional triggering with HCG and conventional luteal support with progesterone
    Intervention: Drug: progesterone 600mg
  • Experimental: Agonist triggering and rec-LH luteal support plus progesterone
    new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
    Intervention: Drug: 300IU rec-LH
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
December 2010
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • < 36years,
  • single blastocystET,
  • FSH < 12

Exclusion Criteria:

  • endometriosis,
  • 3 and 4,
  • pco,
  • frozen sperm
Sexes Eligible for Study: Female
20 Years to 36 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
recombinant LH 1505
Not Provided
Not Provided
Not Provided
Dr Papanikolaou Evangelos, Centre for Reproductive Medicine,UZ Brussel
Universitair Ziekenhuis Brussel
Merck Serono International SA
Study Chair: Paul Devroey Professor or OB-GYN
Universitair Ziekenhuis Brussel
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP